Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Two researchers (A.G
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
The company has already shared some late-stage data on that drug, but the most important trial is one studying the treatment specifically for weight loss
While many people have found success with GLP-1s, others whove taken these diabetes and weight loss medications have experienced severe side effects
:max_bytes(150000):strip_icc()/GettyImages-1470213196-a19fb8f0142542be837a35951bbc80cd.jpg)
US$ 28.18
US$ 26.54
US$ 26.18
US$ 29.43
US$ 22.37
US$ 28.05
US$ 27.83
US$ 21.87
US$ 26.02
US$ 28.16
